Market data including bonds and fuel prices
The miner has instituted projects to decrease the social wage deficit, ranging from education to roads
President laments that scarcely a day passes without reports about men attacking, violating and killing women
Chair Siboniso Duma says province may well support Ramaphosa for a second term
Antitrust suit would be the US justice department’s second case against Google
The Trump-era tariffs on imported metals have been eased for some other countries
In the wake of SAA’s near-demise Comair’s market share crept up to 35%-40% by the time it too collapsed
Ahmad Abouammo was found guilty of turning over personal information of platform users who’d criticised the Saudi royal family
Failure to win on Saturday would put coach Ian Foster and captain under pressure in terms of their future with the team
Nicholas Yell trades SUV for saddle and makes his way from Bot River to Merweville and on to Kruisrivier
The first vaccine for malaria, the mosquito-borne disease that kills about 400,000 people each year, is set to be deployed more widely after more than three decades of work and about $1bn in investment.
The vaccine developed by GlaxoSmithKline (GSK) and its partners won a recommendation from the World Health Organization (WHO) on Wednesday for use in children in Sub-Saharan Africa and other regions with moderate to high transmission. It marks a turning point in a battle against the parasite that causes malaria.
The shot prevented only about four in 10 malaria cases among children who received four doses in a large study, but the injection, along with other measures, could still save hundreds of thousands of lives. Now the focus will shift to getting it to more people following a pilot programme in Africa that began in 2019.
“Today’s recommendation offers a glimmer of hope for the continent, which shoulders the heaviest burden of the disease and we expect many more African children to be protected from malaria and grow into healthy adults,” Matshidiso Moeti, WHO regional director for Africa, said in a statement.
Gavi, the vaccine alliance, GSK and MedAccess announced a financing agreement in August to ensure continued production of the vaccine, the first to prove safe and effective in a large, late-stage trial. Gavi said its board would decide after the WHO decision whether to finance a new malaria vaccination programme for countries in Sub-Saharan Africa.
GSK, which has developed the shot with non-profit organisation Path, committed to donating as many as 10-million doses for the ongoing pilot, and to supply as many as 15-million doses annually.
A study of 6,000 children, published in August, found that the combination of antimalarial drugs and vaccination lowered hospitalisations and deaths from the disease by about 70% after three years. Early development of the shot began around 1984.
Malaria has been a tricky target for vaccinemakers, but researchers are making progress. A shot developed for the disease at the University of Oxford earlier in 2021 became the first to meet a WHO goal of more than 75% efficacy in a mid-stage study.
BioNTech, meanwhile, is seeking to follow its successful Covid-19 vaccine with one to prevent malaria.
More than 2.3-million vaccine doses have been administered, and a product transfer is under way with Bharat Biotech of India. The company pledged to make doses available for no more than 5% above the cost of production.
Bloomberg News. More stories like this are available on bloomberg.com
Would you like to comment on this article? Register (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Published by Arena Holdings and distributed with the Financial Mail on the last Thursday of every month except December and January.